A new era of thoracic oncology? Ex-vivo stereotactic ablative radiosurgery within Ex-vivo Lung Treatment System as a hybrid therapy for unresectable locally advanced pulmonary malignancies. (July 2016)

• Record Type: Journal Article
• Authors: Henkenberens, C.; Zinne, N.; Biancosino, C.; Höffler, K.; Schmitto, J.D.; Bremer, M.; Haverich, A.; Krüger, M.
• Is Part Of: Medical hypotheses. Volume 92(2016)
• Page Start: 31
• Page End: 34
• Publication Date: 2016-07
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2016.04.029
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: The concept of oligometastases is the medical rationale for a local treatment of a limited number of metastatic tumor manifestations. Patients with pulmonary oligometastases are candidates for surgery or radiotherapy, however there are a number of technical issues that limit treatment. Technical issues relating to radiotherapy include organs at risk of irradiation, chest wall toxicity and decreased precision of tumor targeting because of breathing movements. Technical issues relating to surgery include loss of lung parenchyma and unresectability. We propose the hypothesis that ex-vivo radiosurgery as new hybrid technique in thoracic oncology has the capability to overcome these technical issues and will expand the medical spectrum in thoracic oncology. The proposed – highly complex – technique consists of surgical lung explantation, followed by stereotactic radiotherapy during ex-vivo perfusion followed by surgical re-implantation.